Last reviewed · How we verify
Anti-Rabies Vaccine
Stimulates the production of neutralizing antibodies against the rabies virus
Stimulates the production of neutralizing antibodies against the rabies virus Used for Prevention of rabies.
At a glance
| Generic name | Anti-Rabies Vaccine |
|---|---|
| Sponsor | Vac4All |
| Drug class | Inactivated vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Mechanism of action
This vaccine works by introducing a small, harmless piece of the rabies virus to the body, which triggers an immune response and the production of antibodies that can neutralize the virus.
Approved indications
- Prevention of rabies
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-Rabies Vaccine CI brief — competitive landscape report
- Anti-Rabies Vaccine updates RSS · CI watch RSS
- Vac4All portfolio CI